Company intelligence / Profile preview

Cavion

Charlottesville, Virginia, United Statescavion.co ↗

Ownership: Private
Development stage: Phase 2

Overview

Cavion’s lead clinical program, CX‑8998, has been evaluated in the T-CALM trial for essential tremor. The company focuses on modulating the Cav3 channel to address movement disorders and rare epilepsies. As of its acquisition by Jazz Pharmaceuticals in August 2019, it was a clinical-stage company with ongoing trials[1][2].

Therapeutic areas: Neurology
Modalities: Small molecules (specifically T-type calcium channel modulators)
Industry: Biotech

Drug pipeline

1 asset

CX-8998

Phase 2

Indications: Essential tremor

Beyond the preview

Go deeper on Cavion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cavion.

Explore the full profile